Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 10;25(24):13271.
doi: 10.3390/ijms252413271.

MicroRNA-Based Liquid Biopsy for Cervical Cancer Diagnostics and Treatment Monitoring

Maria A Kepsha  1 , Angelika V Timofeeva  1 , Vasiliy S Chernyshev  1 , Denis N Silachev  1 , Elena A Mezhevitinova  1 , Gennadiy T Sukhikh  1
Affiliations
Review

MicroRNA-Based Liquid Biopsy for Cervical Cancer Diagnostics and Treatment Monitoring

Maria A Kepsha et al. Int J Mol Sci. .

Abstract

Despite prevention strategies, cervical cancer remains a significant public health issue. Human papillomavirus plays a critical role in its development, and early detection is vital to improve patient outcomes. The incidence of cervical cancer is projected to rise, necessitating better diagnostic tools. Traditional screening methods like the cytological examination and human papillomavirus testing have limitations in sensitivity and reproducibility. Liquid-based cytology offers some improvements, but the need for more reliable and sensitive techniques persists, particularly for detecting precancerous lesions. Liquid biopsy is a non-invasive method that analyzes cancer-derived products in biofluids like blood, offering potential for real-time monitoring of tumor progression, metastasis, and treatment response. It can be based on detection of circulating tumor cells (CTCs), circulating free DNA (cfDNA), and microRNAs (miRNAs). This review particularly underlines the potential of microRNAs, which are transported by extracellular vesicles. Overall, this article underscores the importance of continued research into non-invasive diagnostic methods like liquid biopsy to enhance cervical cancer screening and treatment monitoring.

Keywords: biomarkers; cervical cancer; diagnosis; exosomes; extracellular vesicles; miRNA; microRNA; treatment monitoring.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Illustration summarizing the stages of CC progression with comparison to a normal cervix and highlighting biofluids that can potentially be used for liquid biopsy. HPV—human papillomavirus; LSIL—low-grade squamous intraepithelial lesions; HSIL—high-grade squamous intraepithelial lesions; CTCs—circulating tumor cells; EVs—extracellular vesicles; ccfRNA—cell-free circulating RNA; ccfDNA—cell-free circulating DNA.
Figure 2
Figure 2
Illustration depicting liquid biopsy where blood or cervicovaginal lavage is obtained from a patient to isolate and characterize EVs, miRNA, and/or IncRNA for eventual diagnostics. EVs—extracellular vesicles.
Figure 3
Figure 3
Cellular localization of experimentally validated gene-targets protein products of CC microRNA markers presented in Table 1 and Table 2, generated by the FunRich (Version 3.1, last accessed on 1 September 2024) program.
Figure 4
Figure 4
Organ expression of target genes for CC miRNA markers. Data are generated using the FunRich (Version 3.1, last accessed on 1 September 2024) tool. The red diamonds indicate the main sites of metastasis for the CC.
Figure 5
Figure 5
Molecular function of gene-targets protein products for CC miRNA markers. Data are generated using the FunRich (Version 3.1, last accessed on 1 September 2024) tool.
Figure 6
Figure 6
Signaling pathways formed by gene-targets protein products for CC miRNA markers. Data are generated by using the FunRich (Version 3.1, last accessed on 1 September 2024) tool.
See this image and copyright information in PMC

References

    1. Viveros-Carreño D., Fernandes A., Pareja R. Updates on cervical cancer prevention. Int. J. Gynecol. Cancer. 2023;33:394–402. doi: 10.1136/ijgc-2022-003703. - DOI - PubMed
    1. Singh D., Vignat J., Lorenzoni V., Eslahi M., Ginsburg O., Lauby-Secretan B., Arbyn M., Basu P., Bray F., Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob. Health. 2023;11:e197–e206. doi: 10.1016/S2214-109X(22)00501-0. - DOI - PMC - PubMed
    1. Chesson H.W., Dunne E.F., Hariri S., Markowitz L.E. The Estimated Lifetime Probability of Acquiring Human Papillomavirus in the United States. Sex. Transm. Dis. 2014;41:660–664. doi: 10.1097/OLQ.0000000000000193. - DOI - PMC - PubMed
    1. Gates A., Pillay J., Reynolds D., Stirling R., Traversy G., Korownyk C., Moore A., Thériault G., Thombs B.D., Little J., et al. Screening for the prevention and early detection of cervical cancer: Protocol for systematic reviews to inform Canadian recommendations. Syst. Rev. 2021;10:2. doi: 10.1186/s13643-020-01538-9. - DOI - PMC - PubMed
    1. World Health Organization . Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. World Health Organization; Geneva, Switzerland: 2020. 52p

MeSH terms